The Benefits of the Hub for Specialty Patients

Picture your childhood bicycle, banana seat and all; now picture the front wheel of that bicycle. That bicycle wheel can serve as a metaphor for the holistic specialty patient experience.

Around the outside of the wheel at the end of the spokes reside the patient, the physician/prescriber, the insurance provider/pharmacy benefit manager, the specialty pharmacy, and the pharmaceutical manufacturer.

Now, picture the same bicycle wheel without a hub in the center holding the spokes together. That’s a bit more challenging because of what the hub signifies within the specialty patient experience.
I remember how confusing the concept of a hub was when I first started my career in specialty pharmacy. I really wish someone had helped me out with a bicycle reference.

The concept of this connector, this interface between the stakeholders in the specialty pharmacy experience, was daunting at first. Once I began to understand the purpose of a hub as the experts that pharmaceutical manufacturers put in charge of streamlining access to their drugs and coordinating patient care, my mental picture got a little bit clearer.

According to an article published in Pharmaceutical Commerce, “Hubs have been around for over a decade, starting out as ‘reimbursement hubs,’ usually provided as a service by manufacturers to help patients and providers navigate the process of obtaining permission to use, and reimbursement for, expensive specialty therapies.”

Hub services have continued to evolve over the years to include big data collection and reporting, prior authorization and appeals, patient assistance programs, quick starts and bridge programs, e-prescription routing, and more. Pharmaceutical manufacturers depend on hubs to act as connectors between all of the “spokes” of the wheel.

Consider this patient example: A specialty patient visits their physician and is started on a new specialty therapy. In order to begin therapy, the physician fills out an electronic form that includes the prescription and patient information, such as benefits and clinical data.

This form is submitted to the hub. When the hub receives the form, they identify which specialty pharmacy is contracted with the patient’s insurance company and/or the pharmaceutical manufacturer to fill the medication.

The hub verifies the patient’s pharmacy or medical benefits to ensure coverage and submit for a prior authorization, if required. In the meantime, the hub contacts the patient and ships them a bridge supply of medication so that they have immediate access to begin therapy while their prior authorization is pending.

The hub also reaches out to the patient’s specialty pharmacy to enroll the patient and facilitate the transition from the bridge supply to the patient’s first order from their pharmacy. When the specialty pharmacy is able to fill the patient’s first order, they follow their standard process and send the dispense data back to the hub.

The hub then compiles these data for the patient, which are sent to the prescriber and manufacturer. This is a fairly common example of the activities performed within a hub to coordinate specialty pharmacy care for patients.

Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 

Related Articles

Direct-to-consumer prescription drug advertising increased from $1.3 billion to $6 billion over the past 20 years, particularly for high-cost biologics and cancer immunotherapies.
Doug Long, vice president of Industry Relations at IQVIA, discusses rebate reform surrounding Medicare Part D and Part B in an interview with Specialty Pharmacy Times.
A phase 3 study evaluated the safety and efficacy of oral paclitaxel versus intravenous paclitaxel monotherapy in patients with metastatic breast cancer.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.